Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
6 search results for:

277 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 28-10-2021 | Breast cancer | News | Article

    Physicians misjudge breast cancer genetic screening barriers for African Americans

    In all, 277 physicians responded to a 49-item survey about their own demographics, knowledge, attitudes, practices, and perceived barriers in providing GCT to patients with breast cancer.

    Author:
    Laura Cowen
    Published in:
    J Clin Oncol 2021; doi:10.1200/JCO.21.01426
  2. 29-09-2019 | Non-small-cell lung cancer | News | Article

    FLAURA shows OS boost with osimertinib in advanced NSCLC

    And it was 31.8 months for their 277 counterparts who instead received the comparator EGFR–TKI (erlotinib 150 mg/day or gefitinib 250 mg/day), for whom the median follow-up was 27.0 months.

    Published in:
    ESMO Congress 2019; Barcelona, Spain: 27 September–1 October
  3. 26-03-2019 | Prostate cancer | Article

    The role of multiparametric MRI in biopsy-naive prostate cancer

    Lebastchi Ah, Pinto PA. Nat Rev Urol 2019; 16: 276–277. doi:10.1038/s41585-019-0173-7 

  4. 09-09-2017 | Non-small-cell lung cancer | ESMO 2017 | Article
    ESMO 2017 in brief

    Osimertinib best in first-line advanced NSCLC setting

    Click here for a video interview with study author Suresh Ramalingam Progression-free survival was significantly longer for the 279 patients randomly assigned to receive osimertinib 80 mg/day than for the 277 given the current standard of care (gefitinib 250 mg/day or erlotinib 150 mg/day), at a median of 18.9 versus 10.2 months and a hazard ratio (HR) of 0.46.

  5. 30-08-2017 | Melanoma | News | Article

    Pembrolizumab survival benefits confirmed for advanced melanoma

    In total, 834 patients with advanced melanoma were enrolled into the multicenter KEYNOTE-006 study and randomly assigned to receive treatment with intravenous pembrolizumab 10 mg/kg every 2 weeks (n=279) or every 3 weeks (n=277) for a maximum of 2 years, or to receive intravenous ipilimumab 3 mg/kg every 3 weeks for four doses (n=278).

    Published in:
    Lancet 2017; Advance online publication
  6. 11-11-2016 | Treatment | Article

    Combinatorial immunotherapy for melanoma

    Pivotal studies in the FDA approval of immune checkpoint inhibitors for melanoma Study Treatment (n) RR PFS OS AEs>G2 CA184-002 32 Ipilimumab+gp100 (403) 6% 2.8 mos 10.0 mos 10–15% Ipilimumab (137) 11% 2.9 mos 10.1 mos 10–15% Gp100 (136) 2% 2.8 mos 6.4 mos 3% CA184-024 33 Dacarbazine+ipilimumab (250) 15% NR a 11.2 mos 38% Dacarbazine+placebo (252) 10% NR a 9.1 mos 4% KEYNOTE-006 35 Pembrolizumab q2w (279) 34% 5.5 mos 74% at 12 mos 13% Pembrolizumab q3w (277) 33% 4.1 mos 68% at 12 mos 10% Ipilimumab (278) 12% 2.8 mos 58% at 12 mos 20% Checkmate-066 36 Nivolumab (210) 40% 5.1 mos 73% at 12 mos 12% Dacarbazine (208) 14% 2.2 mos 42% at 12 mos 18% Checkmate-067 54 Nivolumab+ipilimumab (314) 57% 11.5 mos ND b 55% Nivolumab (316) 44% 6.9 mos ND b 16% Ipilimumab (315) 19% 2.9 mos ND b 27% Abbreviations: AEs>G2, adverse events with toxicity greater than grade 2; FDA, Food and Drug Administration; gp100, glycoprotein 100; mos, months; ND, not determined; NR, no response; OS, overall survival; PFS, progression-free survival; RR, response rate.

    Author:
    D D George, V A Armenio, S C Katz
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.